Table 1.
Baseline characteristics, demographic data, and sarcopenia prevalence of study subjects according to presence of NAFLD or hepatic steatosis status.
| Health Check-Up Participants (N = 1343) |
NAFLD (−) n = 596 |
NAFLD (+) n = 747 |
Hepatic Steatosis Status of Subjects With NAFLD | p-Value * | p for Trend | ||
|---|---|---|---|---|---|---|---|
| Mild FL n = 434 |
Moderate FL n = 249 |
Severe FL n = 64 |
|||||
| Age (year) | 44.13 (13.0) | 48.94 (10.764) | 48.76 (11.2) | 49.59 (10.0) | 46.80 (10.0) | <0.001 | <0.001 |
| Sex Male (n [%]) | 238 (31.9) | 509 (68.1) | 260 (59.9) | 197 (79.1) | 52 (81.3) | <0.001 | <0.001 |
| BMI (kg/m2) | 21.64 (2.56) | 24.88 (3.07) | 23.86 (2.66) | 25.71 (2.60) | 28.54 (3.59) | <0.001 | <0.001 |
| Body weight (kg) | 59.89 (10.66) | 70.27 (11.77) | 66.48 (10.32) | 73.62 (10.26) | 82.83 (13.87) | <0.001 | <0.001 |
| Fat (kg) | 14.29 (4.37) | 19.26 (6.11) | 17.55 (5.20) | 20.43 (5.45) | 26.28 (7.97) | <0.001 | <0.001 |
| ASM (kg) | 18.92 (4.83) | 21.40 (4.47) | 20.45 (4.50) | 22.41 (3.96) | 23.89 (4.45) | <0.001 | <0.001 |
| TSM (kg) | 25.14 (6.12) | 28.36 (5.93) | 27.18 (5.83) | 29.53 (5.57) | 31.80 (5.83) | <0.001 | <0.001 |
| Height (cm) | 165.87 (8.68) | 167.70 (8.26) | 166.61 (8.25) | 168.99 (7.79) | 170.05 (9.01) | <0.001 | <0.001 |
| WC (cm) | 73.01 (7.56) | 82.73 (8.62) | 79.55 (7.60) | 85.55 (6.75) | 93.34 (9.48) | <0.001 | <0.001 |
| Platelet count (×103/µL) | 240.45 (47.43) | 244.23 (51.89) | 243 k (52.64) | 244 k (50.86) | 250 k (51.08) | 0.329 | 0.414 |
| Fasting glucose (mg/dL) | 91.60 (9.91) | 101.08 (17.13) | 98.09 (14.21) | 103.32 (17.40) | 112.64 (26.04) | <0.001 | <0.001 |
| Triglyceride (mg/dL) | 85.25 (39.43) | 144.60 (97.82) | 118.87 (66.40) | 174.21 (120.36) | 203.93 (119.85) | <0.001 | <0.001 |
| Total cholesterol (mg/dL) | 190.23 (33.41) | 199.30 (37.24) | 196.04 (35.73) | 203.22 (38.88) | 206.20 (38.88) | <0.001 | <0.001 |
| HDL Cholesterol (mg/dL) | 60.73 (12.44) | 52.42 (10.49) | 54.84 (10.77) | 49.34 (9.19) | 47.79 (8.54) | <0.001 | <0.001 |
| LDL Cholesterol (mg/dL) | 111.52 (24.46) | 122.01 (27.43) | 118.19 (26.21) | 126.98 (29.47) | 128.65 (29.47) | <0.001 | <0.001 |
| AST (IU/L) | 24.40 (9.71) | 27.99 (13.79) | 25.19 (11.98) | 30.18 (13.79) | 38.45 (18.25) | <0.001 | <0.001 |
| ALT (IU/L) | 19.13 (9.47) | 29.71 (23.49) | 22.68 (15.75) | 35.73 (27.04) | 54.54 (28.89) | <0.001 | <0.001 |
| GGT (IU/L) | 19.08 (15.64) | 31.25 (29.55) | 24.72 (22.61) | 37.08 (32.83) | 52.84 (41.04) | <0.001 | <0.001 |
| T. Bil (IU/L) | 0.90 (0.36) | 0.902 (0.345) | 0.87 (0.33) | 0.93 (0.31) | 0.97 (0.45) | 0.789 | 0.015 |
| Prevalence of sarcopenia, n (%) | |||||||
| ASM/BW*100 | 8 (1.3) | 66 (8.8) | 24 (5.5) | 24 (9.7) | 18 (28.1) | <0.001 | <0.001 |
| ASM/BMI | 8 (1.3) | 43 (5.8) | 21 (4.8) | 15 (6.0) | 7 (10.9) | <0.001 | <0.001 |
| ASM/Ht2 | 12 (2.0) | 6 (0.8) | 5 (1.1) | 1 (0.4) | 0 (0) | 0.055 | 0.284 |
Note: Data are presented as mean (SD) or number (percent); p-value *: Between NAFLD (−) and NAFLD (+) group. t-test or ANOVA were used for continuous variables, respectively. Fisher Exact test was used for categorical variables.